TEVA - Teva Pharmaceutical ...About Us
Get winning Stock, Option and Cryptocurrency trade ideas from pro-traders. Follow their strategies, see how they perform.
|
|
|
| Previous Close | $13.31 | Open | $13.18 |
| Volume | 12.64M | Market Cap | 9.657B |
| Yield | Last Dividend |
| Teva Announces Registration Trials of De... | 02/19/20 |
| TEL AVIV, Israel--(BUSINESS WIRE)--Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced the Phase 2/3 ARTISTS 1 and Phase 3 ARTIS... | |
| Teva Pharm CEO hopes to launch Huntingto... | 02/19/20 |
| Israel-based Teva Pharmaceutical Industries hopes to receive approval to launch its Huntington's treatment Austedo in China this year, the company's c... | |
| TEVA Stock is a Buy but Not an Easy One | 02/19/20 |
| TEVA stock is an ugly name in an even uglier industry. However, it???s also vital to our healthcare system, making it a rough buy. | |
| 3 Analysts Dissect Teva's Q4 Results | 02/13/20 |
| Teva Pharmaceutical Industries Ltd (NYSE: TEVA ) reported fourth-quarter sales and revenues that slightly exceeded estimates but issued a guarded outl... | |
| Good piece exploring whether the recent ... | 02/13/20 |
| Good piece exploring whether the recent signs of a turnaround at Teva Pharmaceuticals are real. ??? | |
| Teva Pharmaceutical CEO on Bringing His ... | 02/12/20 |
| Teva Pharmaceutical Industries CEO K??re Schultz talked with Barron???s about opioid litigation, stabilizing revenues, and what???s next for the compa... | |
| Teva Pharmaceuticals Earnings: TEVA Stoc... | 02/12/20 |
| Teva Pharmaceuticals (TEVA) earnings for the pharmaceutical company's fourth quarter of 2019 have TEVA stock taking off on Wednesday. | |
| Teva Pharmaceuticals Overtakes Key Level... | 02/12/20 |
| The equity is also filling a mid-May bear gap | |
| Thinking about buying stock in Canopy Gr... | 02/12/20 |
| NEW YORK, Feb. 12, 2020 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for CGC, MU, ROKU, SPWR, and TEVA. To see how InvestorsObs... | |
| Teva's stock falls on earnings; Copaxone... | 02/12/20 |
| Shares of Teva Pharmaceutical Industries Ltd. were down 1% in premarket trading on Wednesday after the Israeli drugmaker reported earnings of $110 mil... | |
| New Report Shows Teva Generic Medicines ... | 02/12/20 |
| Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) released a new economic impact report detailing the billions of dollars saved by Teva???s ge... | |
| Teva Reports Fourth Quarter and Full Yea... | 02/12/20 |
| Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today reported results for the year and the quarter ended December 31, 2019. Full-Year 2019 | |
| Q4 Earnings Outlook For Teva | 02/11/20 |
| Teva Pharmaceutical Indus (NYSE: TEVA ) announces its next round of earnings this Wednesday, February 12. Here is Benzinga's everything-that-matters g... | |
| New York Opioid Case A Significant Risk ... | 02/10/20 |
| It appears more and more likely a case against opioid manufacturers and distributors will proceed to trial in New York state, keeping Bank of America ... | |
| Teva Pharmaceutical Industries Ltd. (TEV... | 02/05/20 |
| Teva Pharmaceutical Industries Ltd. (TEVA) closed the most recent trading day at $12.10, moving +0.33% from the previous trading session. | |
| Teva's Two Pivotal Studies on Ajovy in J... | 02/04/20 |
| Teva (TEVA) posts positive results from two phase II/III studies on Ajovy for treating patients with chronic and episodic migraine in Japan. | |
| Teva Announces Positive Top-Line Results... | 02/03/20 |
| TEL AVIV, Israel--(BUSINESS WIRE)--Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced positive results from two Phase 2/3 trial... | |
| In loss for Teva, Fed Circuit revives Ga... | 01/29/20 |
| An appeals court on Wednesday handed a victory to Nestle SE's Galderma unit in its bid to block a generic version of its Soolantra anti-rosacea cream ... | |
| Why Teva Stock Could Be the Next General... | 01/29/20 |
| Teva can handle its debt and deal with its liability from the opioid tragedy. And Teva stock has multiple, positive catalysts. | |
| Teva Announces FDA Approval of AJOVY?? (... | 01/28/20 |
| PARSIPPANY, N.J.--(BUSINESS WIRE)--Teva Pharmaceuticals USA, Inc. an affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today anno... | |
| Bill Miller's mutual fund crushed the ma... | 01/27/20 |
| Mutual fund manager Bill Miller is famous for beating the stock market for a record 15 years in a row in the 1990s and 2000s, and he's maintained his ... | |
| Ironwood/Allergan settle patent dispute ... | 01/22/20 |
| Ironwood Pharmaceuticals (IRWD +0.8%) and licensee Allergan (AGN) have settled patent infringement litigation with Teva Pharmaceutical Industries (TEV... | |
| Ironwood and Allergan Announce Settlemen... | 01/22/20 |
| BOSTON & DUBLIN--(BUSINESS WIRE)--Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) and Allergan plc (NYSE: AGN) announced today that the companies have r... | |
| Teva to Host Conference Call to Discuss ... | 01/15/20 |
| JERUSALEM--(BUSINESS WIRE)--Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that it will issue a press release on its fourth... | |
| Scandal-Ridden Teva Pharmaceutical Is Fi... | 01/08/20 |
| Teva's debt restructuring gives it breathing room through 2021, assuming its legal woes don't get worse. Buy Teva stock at your own risk. | |
| Teva to Present at the 38th Annual J.P. ... | 01/06/20 |
| JERUSALEM--(BUSINESS WIRE)--Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that President & CEO K??re Schultz will present ... | |
| Teva Pharmaceuticals Agrees To Pay $54 M... | 01/06/20 |
| NEW YORK, Jan. 6, 2020 /PRNewswire/ -- James E. Miller of Shepherd, Finkelman, Miller & Shah, LLP ("SFMS")(www.sfmslaw.com), Lead Litigation Counsel f... | |
| Breaking Legal News: TEVA Agrees to Pay ... | 01/06/20 |
| PHILADELPHIA, Jan. 6, 2020 /PRNewswire/ -- Attorney Eric. L. Young announced today that Teva Pharmaceuticals USA, Inc., Teva Neuroscience, Inc., and T... | |
| IN BRIEF: In blow to Teva, Fed Circuit w... | 12/17/19 |
| A federal appeals court on Monday declined to reconsider a patent ruling that blocks Teva Pharmaceutical Industries Limited from selling a generic ver... | |
| Teva Stock Is Nothing but Trouble after ... | 12/09/19 |
| TEVA stock has earned its reputation -- and I mean that in the worst possible way after a recent run of legal issues for pharmaceutical firms. | |
| Buy rating | 02/18/20 |
| Argus Research maintains Buy rating and raises Price Target from $10.00 to $15.00 | |
| Sell rating | 02/14/20 |
| Morgan Stanley maintains Underweight rating and raises Price Target from $8.00 to $13.00 | |
| Strong Buy rating | 02/13/20 |
| Oppenheimer maintains Outperform rating and raises Price Target from $12.00 to $16.00 | |
| Hold rating | 02/13/20 |
| SunTrust Robinson Humphrey maintains Hold rating and raises Price Target from $9.00 to $13.00 | |
| Underperform rating | 02/13/20 |
| B of A Securities maintains Underperform rating and raises Price Target from $8.00 to $11.00 | |
| Hold rating | 02/12/20 |
| CFRA maintains Hold rating and raises Price Target from $11.00 to $13.00 | |
| Hold rating | 02/12/20 |
| Cantor Fitzgerald maintains Neutral rating and raises Price Target from $9.00 to $15.00 | |
| Hold rating | 01/22/20 |
| Wells Fargo maintains Equal-Weight rating and raises Price Target from $8.00 to $10.00 | |
| Hold rating | 11/08/19 |
| PiperJaffray maintains Neutral rating and raises Price Target from $6.00 to $7.00 | |
| Buy rating | 09/30/19 |
| Wells Fargo maintains Market Perform rating and lowers Price Target from $17.00 to $8.00 | |
| Sell rating | 09/06/19 |
| JP Morgan maintains Underweight rating and lowers Price Target from $9.00 to $7.00 | |
| Date | 2020-02-12 (BMO) | Est. (EPS/Rev.) | $0.61/ 4.35B |
| Actual (EPS/Rev.) | $0.62/ $4.47 B | EPS (TTM) | 0 |
| Total Revenue | $1.3B | Total Liabilities | $2.1B |
| Cost of Revenue | $2.5B | Total cash flow | $3.2 |
| Total Assets | $29.98B |
| % Insider | 12.52% | % Institutional | 76.43% |
| Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
| Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
| Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
| Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
| Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
| Service Name | Trader | % Success | |
|---|---|---|---|
| Equity and Teens | Equity and Teens | 100.00 % | Follow |
| Trading | Trading | 99.00 % | Follow |
| Swing for the fences | Gino Baldassano | 75.00 % | Follow |
| Arbitrage Trade Analytics | Royce Wells | 72.00 % | Subscribe |
| Alpha Swing Trades | Jonathan | 69.00 % | Follow |
Get winning Stock, Option and Cryptocurrency trade ideas from pro-traders. Follow their strategies, see how they perform.
We are not a registered investment advisor. All investments involve risk, individual's trading does not guarantee future results or returns. Investors are fully responsible for any investment decisions they make. References to specific securities should not be construed as a recommendation to buy or sell that security only mentioned for informational purposes.
